Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The supplements are made using only vegetarian-sourced ingredients
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The approval is backed by data showing deep, durable responses and manageable tolerability
Subscribe To Our Newsletter & Stay Updated